Jump to content

Sun Pharma: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
updated stake
updated the information for accuracy and relevance
Line 37: Line 37:
}}
}}


'''Sun Pharmaceutical Industries Limited''' ([[Trade name|d/b/a]] '''Sun Pharma''') is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai]], that manufactures and sells [[pharmaceutical formulation]]s and [[Active ingredient|active pharmaceutical ingredients]] (APIs) in more than 100 countries across the globe.<ref>{{cite web|last=Banerjee|first=Avishek|title=Sun Pharma: Global Is Local|url=https://www.businessworld.in/article/Sun-Pharma-Global-Is-Local/27-12-2018-165598/|access-date=2022-11-13|website=BW Businessworld|url-status=live|archive-url=https://web.archive.org/web/20220726111718/https://www.businessworld.in/article/Sun-Pharma-Global-Is-Local/27-12-2018-165598/|archive-date=2022-07-26}}</ref> It is the largest pharmaceutical company in India and the fourth largest specialty [[Generic drug|generic pharmaceutical]] company in the world.<ref name="Business Standard India">{{Cite news|title=Sun Pharmaceuticals Industries Ltd.|work=Business Standard India|url=https://www.business-standard.com/company/sun-pharma-inds-4325/information/company-history|access-date=2022-11-13|url-status=live|archive-url=https://web.archive.org/web/20220809043555/https://www.business-standard.com/company/sun-pharma-inds-4325/information/company-history|archive-date=2022-08-09}}</ref><ref name="Sun Pharma Industries">{{cite web|title=Sun Pharma Industries|url=https://www.forbes.com/companies/sun-pharma-industries/?sh=321e46032e2b|access-date=2022-11-13|website=Forbes|language=en|url-status=live|archive-url=https://web.archive.org/web/20220923143238/http://www.forbes.com/companies/sun-pharma-industries/?sh=6833e349609a|archive-date=2022-09-23}}</ref> The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.<ref name="Business Standard India"/> Its active pharmaceutical products include [[baricitinib]], [[brivaracetam]], and [[dapaglifozin]].<ref>{{cite web|title=Sun Pharmaceutical Industries Ltd: Profile, Pharma Products, History...IBEF|url=https://www.ibef.org/industry/pharmaceutical-india/showcase/sun-pharmaceutical-industries-ltd|access-date=2022-11-13|url-status=live|website=India Brand Equity Foundation|archive-url=https://web.archive.org/web/20220524121509/https://www.ibef.org/industry/pharmaceutical-india/showcase/sun-pharmaceutical-industries-ltd|archive-date=2022-05-24}}</ref>
'''Sun Pharmaceutical Industries Limited''' ([[Trade name|d/b/a]] '''Sun Pharma''') is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai]], that manufactures and sells [[Pharmaceutical formulation|pharmaceutical formulations]] and [[Active ingredient|active pharmaceutical ingredients]] (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty [[Generic drug|generic pharmaceutical]] company in the world. The products cater to a vast range of therapeutic segments covering  psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.  


==History==
==History==


Sun Pharmaceutical Industries Ltd. was established by [[Dilip Shanghvi]] in 1983 in [[Vapi]], [[Gujarat]], with five [[psychiatry]] products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology, ENT, Chest and Consulting Physicians .
Sun Pharmaceuticals was founded by [[Dilip Shanghvi]] in 1983<ref>{{Cite web |title=Know 10 largest Pharmaceutical Companies in India |url=https://www.edudwar.com/top-pharma-companies-in-india/ |access-date=2023-07-28 |website=Edu Dwar}}</ref> in [[Vapi]], [[Gujarat]], with five products to treat [[psychiatry]] ailments. Cardiology products were introduced in 1987<ref name="sunpharma.com">{{cite web|title=Milestones & Recognitions {{!}} Sun Pharmaceutical Industries Limited|url=https://sunpharma.com/milestones-recognitions/|access-date=2021-08-06|website=Sun Pharmaceutical Industries Ltd.|language=en-US}}</ref> followed by [[gastroenterology]] products in 1989. Today it is ranked number one by prescriptions with nine different specialties of doctors in<ref>{{Citation|title=Strategic solutions|date=2013-01-11|url=http://dx.doi.org/10.4324/9780080938486-27|work=Hospitality Marketing|pages=210–219|publisher=Routledge|doi=10.4324/9780080938486-27 |isbn=978-0-08-093848-6|access-date=2021-08-06}}</ref> India and a market leader in cardiology, gastroenterology, ortho,{{Vague|date=May 2022|reason="ortho-what?"}} diabetology, dermatology, urology, vitamins, minerals, and nutrients.<ref>{{Citation|last=Katja S|first=Ziegler|title=AWACS I (Ger)|date=April 2019|url=http://dx.doi.org/10.1093/law-mpeccol/e542.013.542|encyclopedia=Max Planck Encyclopedia of Comparative Constitutional Law|publisher=Oxford University Press|doi=10.1093/law-mpeccol/e542.013.542 |access-date=2021-08-06}}</ref>


The 2014 acquisition of [[Ranbaxy]] made Sun Pharma the largest [https://www.enrico.co.in/ pharma company] in [[India]], the largest Indian pharma company in the US, and the 4th<ref name="Business Standard India"/> largest specialty generic company globally.
The 2015 acquisition of [[Ranbaxy]] made Sun Pharma the largest pharma company in [[India]], the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.


Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;<ref>{{cite web|title=US business remains Sun Pharma's weak spot|url=https://www.fortuneindia.com/enterprise/us-business-remains-sun-pharmas-weak-spot/101421|access-date=2021-08-06|website=www.fortuneindia.com|date=10 November 2017 |language=en}}</ref> in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. [[Food and Drug Administration]] (FDA).<ref>{{cite web |url=http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |title=Creating Lasting Value Investor Presentation - February 2014 |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413142558/http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref>
Around 70% of Sun Pharma’s revenue is generated from international markets.,. The US and India are the largest markets, accounting for over 60% of the company's turnover;. Manufacturing is across 43 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. [[Food and Drug Administration]] (FDA).


Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.<ref>{{Cite journal|date=March 2019|title=Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018|url=http://dx.doi.org/10.1016/j.fos.2019.03.069|journal=Focus on Surfactants|volume=2019|issue=3|page=6|doi=10.1016/j.fos.2019.03.069|s2cid=243155570 |issn=1351-4210}}</ref>
Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.


==Acquisitions and joint ventures==
==Acquisitions and joint ventures==
Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at [[Ahmednagar]] from [[Knoll Pharmaceuticals]] and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in [[Chennai]], mainly for their extensive [[gynaecology]] and [[oncology]] brands. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in [[Detroit]].
Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1995, Sun purchased a bulk drug manufacturing plant at [[Ahmednagar]] from [[Knoll Pharmaceuticals]] and in 1997 acquired MJ Pharma's dosage plant at Halol. . In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in [[Chennai]]. Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals in in North America.


In 1998, Sun acquired a number of respiratory brands from [[Natco Pharma]]. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company acquired a large stake in [[Taro Pharmaceuticals]],<ref>{{cite web|url=http://www.tarousa.com/|title=USA – Taro Pharmaceutical Industries|website=Tarousa.com|access-date=19 July 2018|archive-date=9 June 2002|archive-url=https://web.archive.org/web/20020609193105/http://www.tarousa.com/|url-status=dead}}</ref> amongst the largest generic dermatology companies in the US, with operations across Canada and Israel. The company currently owns ~ 69% stake in Taro, for about $260 million.<ref>{{cite web|url=http://www.sunpharma.com/Acquisition.do|title=Corporate Website: Acquisitions|website=Sunpharma.com|access-date=19 July 2018|archive-url=https://web.archive.org/web/20110810182940/http://www.sunpharma.com/Acquisition.do|archive-date=10 August 2011|url-status=dead|df=dmy-all}}</ref>
In 1998, Sun acquired a number of respiratory brands from [[Natco Pharma]]. Other notable acquisitions include Milmet Labs and Cephalexin and 7ADCA actives manufacturing site (1999) Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).


In 2010, the company acquired a controlling stake in [[Taro Pharmaceuticals]], amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).<ref>{{Cite news|title=Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharmaceutical-merck-co-call-off-2011-jv-sources/articleshow/45154170.cms?from=mdr|access-date=2021-08-06}}</ref>


In 2012, Sun announced acquisitions of two US companies: [[DUSA Pharmaceuticals]], a dermatology device company; and generic pharma company URL Pharma  
In 2012, Sun announced acquisitions of two US companies: [[DUSA Pharmaceuticals]],<ref>{{cite news|url=http://in.reuters.com/article/dusa-sunpharma-idINDEE8A70AL20121108|title=Sun Pharma to buy U.S.-based Dusa for $230 mln|work=Reuters India|date=8 November 2012 |access-date=2 July 2015}}</ref> a dermatology device company; and generic pharma company URL Pharma <ref>{{cite web|url=http://www.takeda.com/news/2012/20121218_5405.html|title=Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical|author=Takeda Pharmaceutical Company Limited|website=Takeda.com|access-date=2 July 2015}}</ref> In 2013, the company announced an R&D joint venture for ophthalmology with the research company, [[Intrexon]].<ref>{{cite web|url=http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|title=Investors – Newsroom – Intrexon|website=Investors.dna.com|access-date=2 July 2015|archive-url=https://archive.today/20140410125413/http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|archive-date=10 April 2014|url-status=dead|df=dmy-all}}</ref>


In 2014  Sun Pharma entered into a licensing agreement with [[Merck & Co.|Merck & Co. Inc.]] to acquire rights for [[Tildrakizumab]] (MK- 3222) for treatment of chronic plaque psoriasis, in order to further strengthen its specialty product pipeline.
On 6 April 2014, Sun Pharma acquired [[Ranbaxy Laboratories|Ranbaxy]] in a US$4 billion landmark transaction to create the world's 5th largest specialty generic pharmaceutical company.<ref>{{Cite news|last=Reporter|first=B. S.|date=2014-04-08|title=Sun Pharma buys Ranbaxy from Japan's Daiichi|work=Business Standard India|url=https://www.business-standard.com/article/companies/sun-pharma-buys-ranbaxy-from-japan-s-daiichi-114040700737_1.html|access-date=2021-08-06}}</ref>


To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.
Then Sun Pharma entered into a licensing agreement with [[Merck & Co.|Merck & Co. Inc.]] for [[Tildrakizumab]] (MK- 3222) in order to further strengthen the specialty product pipeline.<ref>{{Cite news|title=Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-merck-co-inc-enter-into-pact-for-tildrakizumab/articleshow/42730781.cms?from=mdr|access-date=2021-08-06}}</ref>


In 2015, Sun Pharma acquired [[Ranbaxy Laboratories|Ranbaxy]] in a US$ 4 billion landmark transaction to become the world's 5th largest specialty generic pharmaceutical company.
To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.<ref>{{cite web|last=Unnikrishnan|first=C. H.|date=2014-07-16|title=Sun Pharma acquires US injectables firm Pharmalucence|url=https://www.livemint.com/Companies/hBDNNuOdQnSzaO9hWqHimK/Sun-Pharma-buys-USbased-Pharmalucence.html|access-date=2021-08-06|website=mint|language=en}}</ref>


⚫
In March 2015, Sun Pharma announced it had agreed to buy [[GlaxoSmithKline|GlaxoSmithKline's]] opiates business in Australia to strengthen its pain management portfolio.
In December 2014, the [[Competition Commission of India]] approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.<ref>{{cite news|url=http://in.reuters.com/article/ranbaxy-lab-sun-pharma-regulator-idINKBN0JM1AY20141209|title=CCI clears Sun Pharma-Ranbaxy deal|work=Reuters India|date=9 December 2014 |access-date=2 July 2015}}</ref><ref name="auto">{{cite news|url=http://in.reuters.com/article/gsk-sun-pharma-deals-idINL4N0W520E20150303|title=UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia|work=Reuters India|date=3 March 2015 |access-date=2 July 2015}}</ref>


The following year Sun Pharma made some significant acquisitions, including 14 prescription brands from [[Novartis]] in Japan to enter the Japanese market.
⚫
In March 2015, Sun Pharma announced it had agreed to buy [[GlaxoSmithKline|GlaxoSmithKline's]] opiates business in Australia to strengthen its pain management portfolio.<ref name="auto" />


⚫
It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.
The following year Sun Pharma made some significant acquisitions, including 14 brands from [[Novartis]] in Japan to enter the Japanese market.<ref>{{cite web|title=Sun Pharma acquires Novartis brands in Japan for $293 million|url=https://www.thehindubusinessline.com/companies/sun-pharma-acquires-novartis-brands-in-japan-for-293-million/article8410174.ece|access-date=2021-08-06|website=@businessline|date=29 March 2016 |language=en}}</ref>


From 2016 to 2018, Sun Pharma launched some of its new products in the USA. It launched its first branded ophthalmic product, BromSite™ in 2016. In 2017, the company launched its specialty product [[Odomzo]] and then in 2018 another specialty product [[Ilumya]]™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.
⚫
It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.<ref name="Business Standard India"/>


In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence. The company entered the Greater China market by partnering with China Medical System Holdings as well as launched a speciality product, [[Cequa|CEQUAa]], in the United States for the treatment of dry eyes.
From 2016 to 2018, Sun Pharma launched some of its new products in the USA.<ref name="sunpharma.com"/> It launched its first branded ophthalmic product, BromSite™ in 2016.<ref>{{cite web|title=Sun Pharma Launches First Branded Ophthalmic Product in U.S.|url=http://www.ophthalmologyweb.com/1315-News/330803-Sun-Pharma-Launches-First-Branded-Ophthalmic-Product-in-U-S/|access-date=2022-05-12|website=Ophthalmology Web|language=en}}</ref> In 2017, the company launched its specialty product [[Odomzo]]<ref>{{cite web|last=Trivedi|first=Isha|date=2016-12-22|title=Sun Pharma to acquire Novartis's cancer drug Odomzo for $175 mn|url=https://www.livemint.com/Companies/0dD50eq5zcAuTg60uB1qUM/Sun-Pharma-to-acquire-Novartiss-cancer-drug-Odomzo-for-175.html|access-date=2021-08-06|website=mint|language=en}}</ref> and then in 2018 another specialty product [[Ilumya]]™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.<ref>{{cite web|last=Medha|date=2018-10-25|title=New drug launched for moderate-to-severe plaque psoriasis|url=https://speciality.medicaldialogues.in/new-drug-launched-for-moderate-to-severe-plaque-psoriasis|access-date=2021-08-06|website=speciality.medicaldialogues.in|language=en}}</ref>


In 2023, Sun Pharma acquired Concert Pharmaceuticals, a late-stage biotechnology company in USA, a 60% stake in animal healthcare company - Vivaldis Animal Health and Foods Pvt ltd.  from its existing shareholders for Rs 143.30 crore. 
In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.<ref>{{cite web|date=2018-11-27|title=Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment|url=https://www.firstpost.com/business/sun-pharma-to-acquire-japans-pola-pharma-for-1-mn-to-strengthen-presence-in-dermatology-segment-5619901.html|access-date=2021-08-06|website=Firstpost}}</ref> The company entered the Greater China market by partnering with China Medical System Holdings<ref>{{cite web|last=www.ETHealthworld.com|title=Sun Pharma arm enters pact with China Medical System - ET HealthWorld|url=https://health.economictimes.indiatimes.com/news/pharma/sun-pharma-arm-enters-pact-with-china-medical-system/69982236|access-date=2021-08-06|website=ETHealthworld.com|language=en}}</ref> as well as launched a speciality product, [[Cequa]], in the United States for the treatment of dry eyes.<ref>{{cite web|title=Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US|url=https://eyewire.news/articles/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/|access-date=2021-08-06|website=Eyewire News|language=en-US}}</ref>


⚫
In January 2024, Sun Pharma entered into a definitive merger with Taro Pharmaceuticals to acquire the remaining stake in Taro Pharma for $347.73 Million. [[Taro Pharmaceuticals|Taro Pharma]], the U.S.-based unit of India’s leading drugmaker Sun Pharma Ltd, has unveiled a merger agreement with its parent company. Under this agreement, Sun Pharma, the controlling shareholder of Taro, will acquire all outstanding shares of its subsidiary.
In 2023, Sun Pharma to acquired 60% stake in animal healthcare company - Vivaldis Animal Health and Foods Pvt ltd. Sun Pharma Management said it will acquire a 60 percent stake in Vivaldis Health And Foods Private Ltd from its existing shareholders for Rs 143.30 crore.<ref>{{Cite web |date=2023-03-24 |title=Sun Pharma to acquire 60% stake in animal healthcare company Vivaldis |url=https://www.cnbctv18.com/business/companies/sun-pharma-to-acquire-60-stake-in-animal-healthcare-company-vivaldis-16259911.htm |access-date=2023-03-28 |website=cnbctv18.com |language=en}}</ref> In October 2023, Sun Pharma management said it would acquire a 38% stake in EzeRx Health Tech Private Ltd. for Rs 28.69 crore<ref>{{Cite web |date=2023-10-05 |title=Sun Pharma to acquire 38% stake in EzeRx Health Tech for Rs 29 crore |url=https://www.cnbctv18.com/business/companies/sun-pharma-to-acquire-38-stake-in-ezerx-health-tech-for-rs-29-crore-17965131.htm |access-date=2023-10-06 |website=cnbctv18.com |language=en}}</ref> and a 4.04% stake in Agasta Software for Rs 4.5 crore.<ref>{{Cite web |date=2023-10-05 |title=Sun Pharma To Acquire Minority Stakes In Two Companies |url=https://www.bqprime.com/business/sun-pharma-to-acquire-minority-stakes-in-two-companies |access-date=2023-10-06 |website=BQ Prime |language=en}}</ref> In December 2023, Sun Pharma acquired a 16.7% stake in US-based Lyndra Therapeutics for $30 million.<ref>{{Cite web |date=2023-12-18 |title=Sun Pharma to acquire 16.7% in Lyndra Therapeutics for $30 million |url=https://www.moneycontrol.com/news/business/markets/sun-pharma-to-acquire-16-7-in-lyndra-therapeutics-for-30-million-11922451.html |access-date=2023-12-18 |website=Moneycontrol |language=en}}</ref>

⚫
In January 2024, Sun Pharma acquired the Remaining Stake in Taro Pharma For $347.73 Million. [[Taro Pharmaceuticals|Taro Pharma]], the U.S.-based unit of India’s leading drugmaker Sun Pharma Ltd, has unveiled a merger agreement with its parent company. Under this agreement, Sun Pharma, the controlling shareholder of Taro, will acquire all outstanding shares of its subsidiary.<ref>{{cite web |title=Sun Pharma to Acquire Remaining Stake in Taro Pharma For $347.73 Million |url=https://ibmot.com/sun-pharma-to-acquire-remaining-stake-in-taro-pharma/ |website=ibmot |publisher=ibmot |access-date=18 January 2024 |date=18 January 2024}}</ref>


==SPARC==
==SPARC==
Line 88: Line 86:
===2019===
===2019===


* Listed among the [[Forbes]] "World's Best Regarded Companies"<ref name="Sun Pharma Industries"/>
* Listed among the [[Forbes]] "World's Best Regarded Companies"<ref name="Sun Pharma Industries">{{cite web |title=Sun Pharma Industries |url=https://www.forbes.com/companies/sun-pharma-industries/?sh=321e46032e2b |url-status=live |archive-url=https://web.archive.org/web/20220923143238/http://www.forbes.com/companies/sun-pharma-industries/?sh=6833e349609a |archive-date=2022-09-23 |access-date=2022-11-13 |website=Forbes |language=en}}</ref>
* CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019<ref>{{cite web|title=2019 Recipients|url=https://www.mahatmaaward.com/india-2019|access-date=2021-08-06|website=Mahatma Award|language=en}}</ref>
* CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019<ref>{{cite web|title=2019 Recipients|url=https://www.mahatmaaward.com/india-2019|access-date=2021-08-06|website=Mahatma Award|language=en}}</ref>
* Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum<ref>{{cite web|title=ACEF-Asian Leaders Forum and Awards|url=https://www.customerengagement.asia/winners/2019_September.html|access-date=2021-08-06|website=www.customerengagement.asia}}</ref>
* Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum<ref>{{cite web|title=ACEF-Asian Leaders Forum and Awards|url=https://www.customerengagement.asia/winners/2019_September.html|access-date=2021-08-06|website=www.customerengagement.asia}}</ref>

Revision as of 07:42, 20 March 2024

Sun Pharmaceutical Industries Limited
Company typePublic
ISININE044A01036
IndustriePharmaceuticals
Gegründet1983; 41 years ago (1983)
GründerDilip Shanghvi
Hauptsitz
Mumbai
,
Indien
Area served
Worldwide
Key people
Dilip Shanghvi (MD)
ProduktePharmaceutical drugs, generic drugs, antiviral drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health
RevenueIncrease ₹44,520 crore (US$5.3 billion)[1] (2023)
Increase ₹9,408 crore (US$1.1 billion)[1] (2023)
Increase ₹8,560 crore (US$1.0 billion)[1] (2023)
Total assetsIncrease ₹80,743 crore (US$9.7 billion)[1] (2023)
Total equityIncrease ₹55,995 crore (US$6.7 billion)[1] (2023)
OwnerDilip Shanghvi (54.48% stake)[1]
Number of employees
37,000+ (2021)
Websitesunpharma.com
Footnotes / references
[2][3]

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering  psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.  

History

Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology, ENT, Chest and Consulting Physicians .

The 2015 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.

Around 70% of Sun Pharma’s revenue is generated from international markets.,. The US and India are the largest markets, accounting for over 60% of the company's turnover;. Manufacturing is across 43 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).

Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.

Acquisitions and joint ventures

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1995, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and in 1997 acquired MJ Pharma's dosage plant at Halol. . In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai. Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals in in North America.

In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Cephalexin and 7ADCA actives manufacturing site (1999) Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).

In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.

In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company; and generic pharma company URL Pharma  

In 2014  Sun Pharma entered into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis, in order to further strengthen its specialty product pipeline.

To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.

In 2015, Sun Pharma acquired Ranbaxy in a US$ 4 billion landmark transaction to become the world's 5th largest specialty generic pharmaceutical company.

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.

The following year Sun Pharma made some significant acquisitions, including 14 prescription brands from Novartis in Japan to enter the Japanese market.

It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.

From 2016 to 2018, Sun Pharma launched some of its new products in the USA. It launched its first branded ophthalmic product, BromSite™ in 2016. In 2017, the company launched its specialty product Odomzo and then in 2018 another specialty product Ilumya™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence. The company entered the Greater China market by partnering with China Medical System Holdings as well as launched a speciality product, CEQUAa, in the United States for the treatment of dry eyes.

In 2023, Sun Pharma acquired Concert Pharmaceuticals, a late-stage biotechnology company in USA, a 60% stake in animal healthcare company - Vivaldis Animal Health and Foods Pvt ltd.  from its existing shareholders for Rs 143.30 crore. 

In January 2024, Sun Pharma entered into a definitive merger with Taro Pharmaceuticals to acquire the remaining stake in Taro Pharma for $347.73 Million. Taro Pharma, the U.S.-based unit of India’s leading drugmaker Sun Pharma Ltd, has unveiled a merger agreement with its parent company. Under this agreement, Sun Pharma, the controlling shareholder of Taro, will acquire all outstanding shares of its subsidiary.

SPARC

In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2013, SPARC declared revenue of ₹873 million.[4] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update[5] of its pipeline (NDDS).[6]

Awards

Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list [7] in a study conducted by BlueBytes,[8] a leading Media Analytics firm in association with TRA Research,[9] a brand insights organization (both a part of the Comniscient Group).

2019

  • Listed among the Forbes "World's Best Regarded Companies"[10]
  • CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019[11]
  • Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum[12]

2020

  • Listed among the Forbes World's Best Employers 2020[13]
  • Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list[14]

2021

  • Received the Golden Peacock Award for Corporate Social Responsibility, 2020[15]
  • Won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals[16]
  • Received the Distribution Industry Award for Notable Achievements in Healthcare (DIANA) award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution Alliance Conference 2021[17]
  • Recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards[18]

References

  1. ^ a b c d e f "Sun Pharma Profit & Loss Statement".
  2. ^ "Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results" (PDF). mypharmaproducts.store. Sun Pharmaceutical. 4 February 2019. Retrieved 4 February 2019.
  3. ^ "Annual Report 2020-21" (PDF). Sun Pharmaceutical Industries. Retrieved 12 May 2022.
  4. ^ "Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts". Moneycontrol.com. Retrieved 2 July 2015.
  5. ^ "Investor Update on R&D Pipeline" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 12 May 2022.
  6. ^ "SUN PHARMA ADVANCED RESEARCH COMPANY". Sunpharma.in. Archived from the original on 2 February 2018. Retrieved 2 July 2015.
  7. ^ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". Archived from the original on 20 August 2016. Retrieved 18 August 2016.
  8. ^ "Blue Bytes". Bluebytes.info. Retrieved 19 July 2018.
  9. ^ "TRA". Trustadvisory.info. Retrieved 19 July 2018.
  10. ^ "Sun Pharma Industries". Forbes. Archived from the original on 23 September 2022. Retrieved 13 November 2022.
  11. ^ "2019 Recipients". Mahatma Award. Retrieved 6 August 2021.
  12. ^ "ACEF-Asian Leaders Forum and Awards". www.customerengagement.asia. Retrieved 6 August 2021.
  13. ^ "The World's Best Employers 2020". Forbes. Retrieved 6 August 2021.
  14. ^ "Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations | 28 comments". www.linkedin.com. Retrieved 6 August 2021.
  15. ^ "Institute of Directors, India on LinkedIn: GPA Results sheet for CSR & HR Excellence - 2020". www.linkedin.com. Retrieved 11 February 2022.
  16. ^ Award for Sectoral Performance based category-Pharmaceuticals- Sun Pharmaceutical Industries Limited. Dun & Bradstreet India. 19 August 2021. Archived from the original on 9 February 2022. Retrieved 18 February 2022 – via YouTube.
  17. ^ HDA - Healthcare Distribution Alliance [@HDAconnect] (14 June 2021). ".@SunPharma_Live wins the Best New Product Introduction or Promotion DIANA in the "Generic Pharmaceutical Products" category for Epoprostenol. https://t.co/XCYZlqLOCE" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022 – via Twitter.
  18. ^ Indo-American Chamber of Commerce [@iaccindia] (13 October 2021). "Sun Pharma - The winner of 'Excellence in Innovation' for the year 2021. Mr. C S Muralidharan, Chief Financial Officer of Sun Pharma had collected the award for #SunPharma. #IACCIndia #CorporateAwards #AwardNight #winner #IndoUSrelation #IndoAmericanCorporateExcellenceAwards https://t.co/PxFksVw48c" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022 – via Twitter.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sun_Pharma&oldid=1214648166"